Lisaca, Reynalyn .

HRN: 28-43-49  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/18/2026
CEFUROXIME 1.5GM (VIAL)
01/18/2026
01/19/2026
IV
1.5g
Q8
S/P NSVD; T/C Endometritis
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: